A program that takes care of severely disabled adults during the daytime is on the brink of shutting down over delays in processing government paperwork. Both the Department of Integrated Services ...
Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.
Michael Dickinson, MBBS, FRACP, Lead of the Aggressive Lymphoma Disease Group at Peter MacCallum Cancer Centre ... The Company’s lead programs aim to overcome the current limitations of ex vivo ...